Literature DB >> 12387578

Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease.

A Kalela1, T A Koivu, T Sisto, J Kanervisto, M Höyhtyä, P Sillanaukee, T Lehtimäki, S T Nikkari.   

Abstract

Expression of several matrix metalloproteinases (MMPs) in atherosclerotic plaques has been well documented, and there are findings to indicate that arterial inflammation is reflected in increased serum concentration of matrix metalloproteinase-9 (MMP-9). In coronary atherosclerosis, there is enhanced expression of this MMP, which may be predictive of the severity of the disease. We determined the concentrations of serum MMP-9 in 61 patients (47 males, 14 females) who had >50% obstruction in one or more coronary arteries as assessed by coronary angiography before bypass surgery. In a control group of 19 patients (9 males, 10 females) there were no pathological findings in coronary angiography. ANOVA showed that serum MMP-9 concentrations were highest in patients with 3-vessel coronary artery disease (CAD) (57.3+/-39.1 microg/L, p=0.011). The difference remained statistically significant after adjustment for age, diabetes and sex (p=0.025, ANCOVA). When the groups were compared with each other, serum MMP-9 concentration was higher in the patients with 3-vessel CAD than in those with 1- or 2-vessel CAD (40.4+/-25.1 microg/L, p=0.044) or in the controls (32.2+/- 16.1 microg/L, p=0.007). These results show that serum MMP-9 is elevated in patients with severe coronary stenosis compared with controls. Since MMP-9 has been suggested to reflect inflammation in atherosclerotic plaques, it may be useful in the evaluation of the severity of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387578     DOI: 10.1080/00365510260296483

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  15 in total

Review 1.  Inflammatory biomarkers and coronary heart disease: from bench to bedside and back.

Authors:  Gina Biasillo; Milena Leo; Roberta Della Bona; Luigi Marzio Biasucci
Journal:  Intern Emerg Med       Date:  2010-02-25       Impact factor: 3.397

2.  Environmental arsenic exposure and serum matrix metalloproteinase-9.

Authors:  Jefferey L Burgess; Margaret Kurzius-Spencer; Mary Kay O'Rourke; Sally R Littau; Jason Roberge; Maria Mercedes Meza-Montenegro; Luis Enrique Gutiérrez-Millán; Robin B Harris
Journal:  J Expo Sci Environ Epidemiol       Date:  2012-12-12       Impact factor: 5.563

3.  Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease.

Authors:  Seyed Reza Mirhafez; Amir Avan; Mohammad Tajfard; Shabnam Mohammadi; Mohsen Moohebati; Arash Fallah; Hamed Ghazavi; Hossein Savadi; Majid Ghayour Mobarhan
Journal:  J Clin Lab Anal       Date:  2016-12-02       Impact factor: 2.352

4.  Relation of dietary inorganic arsenic to serum matrix metalloproteinase-9 (MMP-9) at different threshold concentrations of tap water arsenic.

Authors:  Margaret Kurzius-Spencer; Robin B Harris; Vern Hartz; Jason Roberge; Chiu-Hsieh Hsu; Mary Kay O'Rourke; Jefferey L Burgess
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-01-21       Impact factor: 5.563

5.  The Relationship of Serum Soluble Fas Ligand (sFasL) Level with the Extent of Coronary Artery Disease.

Authors:  Asife Sahinarslan; Bulent Boyaci; Sinan Altan Kocaman; Salih Topal; Ugur Ercin; Kaan Okyay; Neslihan Bukan; Ridvan Yalçin; Atiye Cengel
Journal:  Int J Angiol       Date:  2012-03

Review 6.  Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.

Authors:  Jochen Metzger; Peter B Luppa; David M Good; Harald Mischak
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

Review 7.  Matrix metalloproteinases and myocardial infarction.

Authors:  Wannakorn Phatharajaree; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

Review 8.  Matrix metalloproteinases and atherosclerosis.

Authors:  Noboru Watanabe; Uichi Ikeda
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

9.  Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke.

Authors:  Chongke Zhong; Jingyuan Yang; Tan Xu; Tian Xu; Yanbo Peng; Aili Wang; Jinchao Wang; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Yonghong Zhang; Jiang He
Journal:  Neurology       Date:  2017-07-26       Impact factor: 9.910

10.  Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction.

Authors:  Savas Guzel; Ozden Serin; Eda Celik Guzel; Banu Buyuk; Güzin Yılmaz; Guvenc Güvenen
Journal:  Korean J Intern Med       Date:  2013-02-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.